Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.

Authors :: Lederman, Robert J.
Tenaglia, Alan N.
Anderson, R. David
Hermiller, James B.
Rocha-Singh, Krishna
Mendelsohn, Farrell O.
Hiatt, William R.
Moon, Thomas
Whitehouse, M.J.
Annex, Brian H.
Lederman, R J
Tenaglia, A N
Anderson, R D
Hermiller, J B
Rocha-Singh, K
Mendelsohn, F O
Hiatt, W R
Moon, T
Annex, B H
Source :: American Journal of Cardiology. 7/15/2001, Vol. 88 Issue 2, p192-192. 6p. 1 Diagram, 2 Charts.
Publication Year :: 2001
Abstract: The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC. [ABSTRACT FROM AUTHOR]

Subjects :: *BLOOD vessels
*NEOVASCULARIZATION
*GROWTH factors
*RECOMBINANT proteins
*CLINICAL trials
*COMPARATIVE studies
*EXPERIMENTAL design
*INTERMITTENT claudication
*RESEARCH methodology
*MEDICAL cooperation
*RESEARCH
*EVALUATION research
*RANDOMIZED controlled trials
*BLIND experiment
*THERAPEUTICS

Full Text Access

Tools